NCT04268953已完成1 期
A Phase 1, Single-centre, Multiple-dose, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of the AC-SD-03 Formulation of Tricaprilin in Healthy Older Volunteers
Cerecin1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2020年2月27日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Safety and tolerability of multiple-dose administrations of tricaprilin formulated as AC-SD-03 administered using a titration scheme in healthy older volunteers
研究概览
简要总结
This is a Phase I, single center, open label, multiple dose, pharmacokinetic (PK) study recruiting healthy older subjects.
研究设计
- 研究类型
- Interventional
- 干预模型
- Sequential
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy, adult, males or females, age 50 years and above, at Screening.
- •Subject must be in reasonably good health as determined by the investigator based on a detailed medical history, full physical examination (including blood pressure and pulse rate measurement), 12 lead ECG and clinical laboratory tests. Subjects with mild, chronic, stable disease (e.g., controlled hypertension, Type 2 diabetes, etc) will be permitted to enrol.
- •Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at Screening.
- •Agrees to comply with study procedures including the confinement period of 28 days.
- •Subject is able and willing to consume a prescribed full breakfast, lunch and dinner while confined in the CRU. Subject does not have specific dietary requirements (vegetarian, vegan, lactose-free, low-fat, etc.).
- •Subject is not consuming a ketogenic diet (defined by consumption of < 50 gm carbohydrates per day).
- •A non vasectomized male subject must agree to use a condom or abstain from sexual intercourse during the study and for 90 days following last dose of AC-SD
- •No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to Screening. A subject who has been vasectomized less than 4 months prior to Screening must follow the same restrictions as a non vasectomized male.
- •Female subjects must be either surgically sterile or 2 or more years post-menopause.
- •Has given voluntary, written informed consent to participate in the study.
排除标准
- •History or presence of alcoholism or substance abuse disorder within the last year.
- •Positive urine drug screen at Screening or Check-In.
- •Subject is currently actively using MCTs, ketone esters, or other ketogenic products or is following a ketogenic diet.
- •Clinically significant abnormal laboratory results at Screening that in the opinion of the PI preclude participating in this study
- •Participation in another clinical trial within 30 days prior to Check-In.
- •Subject has a known allergy to the study drug's active or inactive ingredients.
- •Subject has been following a ketogenic diet (or other diet incompatible with the on-study diet), in the opinion of the investigator.
- •Unable to refrain from, or anticipates the use of drugs other than allowed products, including prescription and non-prescription medications, beginning 14 days prior to the first dose and throughout the study.
- •Allowed medications include anti-hypertensive agents, statins, aspirin in a dose of 100 mg or less per day for prophylaxis.
- •Paracetamol (acetaminophen), up to 4 g per 24 hour period, or ibuprofen (up to 1200 mg per 24-hour period) may be permitted during the study.
- •Herbal remedies and vitamin supplements are permitted in usual doses (not hyper supplementation) so long as subject has been on stable amounts for at least 6 weeks.
- •Agents being taken to improve memory or cognition are not allowed, whether herbal, 'natural' or pharmaceutical.
- •Subject is known HIV, HBV or HCV positive, or has a positive test at Screening.
- •Any other condition which, in the investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject.
研究组 & 干预措施
AC-SD-03
Experimental
Study drug administered concurrently with a standard meal
干预措施: Tricaprilin (Drug)
结局指标
主要结局
Safety and tolerability of multiple-dose administrations of tricaprilin formulated as AC-SD-03 administered using a titration scheme in healthy older volunteers
时间窗: 32 days
TEAE incidence rate
次要结局
- Pharmacokinetics (PK) parameters of Total Ketones levels after multiple dose of AC-SD-03 using AUC(0-t)(28 days)
- Pharmacokinetics (PK) parameters of Total Ketones levels after multiple dose of AC-SD-03 using Cmax(28 days)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Study Evaluating Betrixaban in Pediatric ParticipantsVTE ProphylaxisNCT03346083Alexion Pharmaceuticals, Inc.21
已完成
1 期
The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy SubjectsPharmacokineticsNCT05517616Ascentage Pharma Group Inc.6
已完成
1 期
To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal InsufficiencyResistant to Gram-positive, Gram-negative and Anaerobic BacteriaNCT06672276Chia Tai Tianqing Pharmaceutical Group Co., Ltd.32
已完成
1 期
LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With CrizotinibNon-Small Cell Lung CancerNCT02040870Novartis Pharmaceuticals103
已完成
1 期
A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic FunctionHepatic ImpairmentNCT06734208Genentech, Inc.31